Opinion

Video

Tailoring CDK4/6 Inhibitor Treatment to Patient Needs

A leading breast cancer specialist examines the growing role of CDK4/6 inhibitors in the adjuvant treatment of HR+/HER2- early breast cancer, citing the monarchE and NATALEE trials, and explores patient and disease-related factors that guide the decision to incorporate CDK4/6 inhibitors in this context.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Video features 3 KOLs
timothy caulfield, JD
dr ibrahim aldoss
dr anna sureda
Related Content
CH LogoCenter for Biosimilars Logo